Endothelial ADAM17 Expression in the Progression of Kidney Injury in an Obese Mouse Model of Pre-Diabetes

Vanesa Palau1, Josué Jarrín1, Sofia Villanueva1

  • 1Department of Nephrology, Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques, 08003 Barcelona, Spain.

Insights

Endothelial ADAM17 (Disintegrin and metalloproteinase domain 17) contributes to kidney damage in obesity and pre-diabetes. Deleting ADAM17 in endothelial cells protected against high-fat diet-induced renal inflammation and fibrosis.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Disintegrin and metalloproteinase domain 17 (ADAM17) promotes inflammation and fibrosis by shedding TNF-α and TGF-α.
  • Obesity, inflammation, and diabetes are linked, with ADAM17 expression increasing in renal damage, particularly in endothelial cells.
  • Endothelial ADAM17's role in diet-induced kidney disease remains uncharacterized.

Purpose of the Study:

  • To investigate the role of endothelial ADAM17 in a high-fat diet (HFD)-induced obesity and pre-diabetes mouse model.
  • To analyze the impact of endothelial-specific ADAM17 deletion on renal function, histology, and inflammation.

Main Methods:

  • Created endothelial-specific Adam17 knockout (KO) mice.
  • Fed KO and wild-type (WT) littermates a HFD or standard chow for 22 weeks.
  • Assessed glucose tolerance, urinary albumin-to-creatinine ratio, renal histology, macrophage infiltration, and galectin-3 levels.

Main Results:

  • Obese mice exhibited higher body weight, blood glucose, and impaired glucose homeostasis.
  • Obese WT mice showed increased albuminuria, glomerular hypertrophy, mesangial expansion, and tubular fibrosis with elevated galectin-3.
  • Endothelial Adam17 KO mice displayed reduced albuminuria, glomerular mesangial index, tubular galectin-3, and macrophage infiltration compared to obese WT mice.

Conclusions:

  • Endothelial ADAM17 plays a significant role in mediating renal inflammation and fibrosis in diet-induced obesity and pre-diabetes.
  • Targeting endothelial ADAM17 may offer a therapeutic strategy for preventing or mitigating kidney damage in metabolic diseases.